Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Silo Pharma, Inc.

  • SARASOTA, Florida
  • Public · NASDAQ: SILO
  • 3 employees
$6.4MMarket cap
$72.1KRevenue · FY2025
-$4.2MNet income
3Employees
SILONASDAQ
2012IPO

About Silo Pharma, Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$72.1K
Net income
-$4.2M
Total assets
$7.6M
Market cap
$6.4M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: SILO

15-minute delayed · data by Polygon.io

Market cap
$6.4M
Open
Day range
Prev close
Volume
IPO date
Jan 5, 2012

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review Silo Pharma, Inc..

Write a review
Explore

Similar companies

Browse all →